Skip Navigation

Medical University | MUSC Hospital | College of Medicine | Directory

Department of Psychiatry and Behavioral Sciences

MUSC logo

ART


Department of Psychiatry

History of the Department

Patient Services

Divisions & Programs

Education & Training

Faculty

Continuing Education

Philanthropy & Giving

Contact Us

Directions

About Charleston

Intranet

Visit us on Facebook Twitter  You Tube
 




 

   

   

   

  
 
 

 

 

Clinical Neuroscience Division

 
Actively Recruiting Research Studies

Alcohol

A Double-Blind, Placebo-Controlled Trial of Lamotrigine in Individuals with Bipolar Disorder and Comorbid Alcohol Dependence
The purpose of this study is to learn whether Lmotrigine (also called Lamictal) is safe and effective in the treatment of alcohol dependence in adults who also have bipolar disorder. This study also will investigate if levels of cognitive functioning (e.g. reasoning, thinking) are related to the presence of bipolar disorder and alcohol dependence, alcohol dependence alone, bipolar disorder alone, or the presence of any psychiatric condition. If you use alcohol, have problems with manic depression (bipolar disorder), or both you may be eligible to participate. There are a total of 15 research visits that will take place over the course of 18 weeks. Study medication will be provided at no charge and compensation is available.
Recruitment Contact: Helena Brenner, 843-792-0572 or
brennerh@musc.edu


Cocaine

A Pilot Randomized Controlled Trial of N-acetylcysteine for Cocaine Relapse Prevention
The goal of the proposed study is to evaluate the efficacy and safety of N-acetylcysteine in preventing relapse in cocaine dependent individuals who have achieved abstinence after receiving residential treatment. 
Recruitment Contact:  Kristina Huebner, 843-792-1901 or
huebnerk@musc.edu

Treatment Implications of Beta-blockade effects on memory for cocaine craving
This research study will look at the potential an untested medication has to reduce cocaine cravings in people who are cocaine dependent. It is hoped that the results of this study will lead to a medication that can be used during treatment for cocaine dependence and that it may even be used for other substance addictions.
Recruitment Contact: Tara Abbott / Project Coordinator, 843-792-2286 or
abbottt@musc.edu

Oxytocin in Cocaine Dependence
Stress is likely involved in relapse to cocaine use. This project will investigate the role oxytocin may play in the stress response in cocaine-dependent men and women and examine how oxytocin may impact brain activity in individuals exposed to cocaine-related cues.
Recruitment Contact: Lisa Nunn, 843-792-0476 or
jenkinli@musc.edu

A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/week or 300 mg/week) as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
This treatment study is investigating the effectiveness of the medication TV-1380 in reducing cocaine use in people who frequently use cocaine. A contingency management intervention and cognitive behaviroal therapy sessions are incorporated to encourage study engagement and retention.
Contact: Lisa Nunn 792-0476 or jenkinli@musc.edu


Depression—Pain—Postpartum Depression—Stress

National Network of Depression Centers Clinical Care Registry
This study aims to establish a patient registry, collecting data in patients with mood disorders who are treated in routine clinical care at the participating centers in the National Network of Depression Centers (NNDC). Participants will be followed during the course (s) of their treatment. Data will be uploaded into the NNDC Data Coordinating Center database. Recruitment Contact: Dr. Constance Guille, 843-792-6190 or guille@musc.edu  

Effect of perceived stimulus control on pain perception in healthy and depressed adults
The purpose of this study is to first investigate differences in healthy and depressed participants in the effects of perceived controllability on pain perception. Next we will determine if Transcranial Magnetic Stimulation (TMS) moderates perceived controllability on pain perception in those undergoing TMS treatment for depression. The study will help us to better understand the role of perceived control in depression as well as increase our understanding of the mechanism of action of TMS for the treatment of depression. Recruitment Contact: Dr. Constance Guille, 843-792-6190 or guille@musc.edu  

The Identification of Biological Markers of Postpartum Depression
Postpartum depression (PPD) is a debilitating mood disorder that occurs in 15-20% of childbearing women. Although several psychosocial risk factors for PPD have been identified, a substantial proportion of the risk for the disorder remains unexplained and biological contributors are unclear. The identification of biological markers in PPD will substantially improve our ability to detect and intervene prior to the onset of the disease, uncover novel disease pathways and ultimately, produce better treatments for patients suffering from PPD. The purpose of the study is to identify biological markers of PPD. Recruitment Contact: Dr. Constance Guille, 843-792-6190 or guille@musc.edu  

The effects of sleep disruption on pain and stress response in healthy volunteers
The purpose of this study is to determine effects of sleep disruption on changes in laboratory measurements of pain, somatic symptoms, and HPA axis reactivity in healthy individuals.
Contact Dr. Kelly Barth stephen@musc.edu)


Marijuana

Vilazodone Treatment for Marijuana Dependence
This 8-week treatment study is investigating the effectiveness of the medication vilazodone in reducing marijuana use in people who frequently use marijuana. A contingency management intervention and motivational enhancement therapy sessions are incorporated to encourage study engagement and retention. Visit our website for additional information: www.mjresearchstudy.com
Contact: Jessica 792-5819

Buspirone Treatment for Marijuana Dependence
This 12-week treatment study is investigating the effectiveness of the medication buspirone in reducing marijuana use in people who frequently use marijuana. A contingency management intervention and motivational enhancement therapy sessions are incorporated to encourage study engagement and retention. Visit our website for additional information: www.mjresearchstudy.com
Contact: Jessica 792-5819

Effect of Oxytocin on Craving and Therapy Response in Marijuana-Dependent Individuals
This non-treatment study is investigating the impact of intranasal oxytocin on therapy effectiveness, drug craving, and marijuana use outcomes following a brief, one-time therapy intervention. Contact: Jessica 792-5819

Achieving Cannabis Cessation—Evaluating N-Acetylcysteine Treatment (ACCENT)
The primary objective of this study, conducted across six sites nationally within the National Institute on Drug Abuse Clinical Trials Network, is to evaluate the impact of N-acetylcysteine 1200 mg versus matched placebo twice daily, added to contingency management, on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50). This is a Phase 3, 12-week, intent-to-treat, two-group, double-blind, randomized, placebo-controlled trial with one follow-up visit approximately 4 weeks post-treatment.
Contacts: Susan Sonne, PharmD 792-5221 or Ricardo Cantu 792-8894


PTSD & Substance Abuse

Exploring Sex Differences in the Neural Correlates of PTSD: Impact of Oxytocin
The purpose of the study is to examine the impact of oxytocin administration on brain activity to aversive social cues in men and women with PTSD associated with childhood trauma and men and women without PTSD but who also have a significant history of childhood trauma.
Recruitment contact: Todd LeMatty 792-8179 or
lematty@musc.edu

Treatment Implications of Trauma Memory Modulation for PTSD & Alcohol Dependence
Researchers at MUSC are looking for individuals who have been victims of violent crime and/or sexual assault and drink alcohol regularly. You may benefit from participating in a research study. This will require one overnight stay, and a follow up. This is a medication study. Compensation will be provided. 18 years or older please.
Recruitment Contact: Tara Abbott/ Project Coordinator, 843-792-2286 or
abbottt@musc.edu  

IntegratedTreatment of OEF/OIF Veterans with PTSD and Substance Use
Are you an OEF/OIF Veteran or Service Member?  Did you serve in the Iraq or Afghanistan or support those operations? If so, did you experience or witness a traumatic event, such as combat or a serious injury? Do you find that you are still affected by the event? For example, do you notice that you feel jumpy or irritable? Do you avoid situations that remind you of what happened, or have nightmares or unwanted memories? And do you find that you drink alcohol or use drugs to help cope with how the trauma has affected you? If so, you may be eligible to participate in a MUSC clinical trial testing a new therapy. You will be compensated for your time and information is kept strictly confidential. Transportation to appointments may be available.
Recruitment Contact: Frank Beylotte, 843-792-2522


Smoking

A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation
This is a placebo-controlled smoking cessation treatment study for adolescents ages 14-21. After assessment and inclusion into the study, participants will be randomized to receive a 12-week double blind course of varenicline or placebo. All participants will concurrently participate in a contingency management (CM) intervention, specifically designed to reinforce participant retention. Recruitment Contact: 792-4097 or smokingstudy@musc.edu

Gender-Sex Hormone interface with craving and stress-related changes in smoking
During a 2-week period, nicotine dependent participants will use the newly developed and validated Cue Reactivity Ecological Momentary Assessment (CREMA) software implemented on a widely available personal digital assistant (iPhone) to provide real-time responses to smoking-related and neutral picture cues presented multiple times daily in their natural environment. Recruitment Contact: 792-4097 or smokingstudy@musc.edu


 
 

 

About the Division
CND Faculty & Staff
Publications
Currently Recruiting Studies
Resources
Seminar Schedules
Addiction Psychiatry Fellowship
BIRCWH
CTN
DART
NIDA K12
SCOR
WRC
Contact Us




Aimee L. McRae-Clark,
PharmD, BCPP

Director,
Clinical Neuroscience Division

Professor, 
Department of
 Psychiatry and Behavioral Sciences